Among the army of acronyms that marches across the pages of biomedical research reports is PPAR, standing for "perixosome proliferator-activated receptor," which entered the limelight earlier this month as a result of a ruling from an outfit known by yet another acronym: the FDA. (BioWorld Financial Watch) Read More